Zura Bio
Logotype for Zura Bio Limited

Zura Bio (ZURA) investor relations material

Zura Bio Registration filing summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Zura Bio Limited
Registration filing summary27 Oct, 2026

Company overview and business model

  • Clinical-stage biotech developing antibody medicines for serious autoimmune and inflammatory diseases with unmet medical need; focus on immune pathways supported by translational and clinical evidence.

  • Lead candidate tibulizumab (ZB-106), in Phase 2 trials, is designed to block IL-17 and B-cell activating factor; pipeline also includes clinical-stage antibody assets.

Financial performance and metrics

  • Net tangible book value at September 30, 2026 was $177.7 million, or $1.84/share; under the assumed ATM sale, adjusted value would be $287.8 million, or $2.24/share.

  • As of September 30, 2026, 96,306,411 Class A shares were outstanding; outstanding options, restricted share units, pre-funded warrants and plan reserves create potential additional dilution.

  • Significant losses have been incurred since inception; significant losses are expected for the foreseeable future, with substantial additional capital required to fund operations.

Use of proceeds and capital allocation

  • ATM net proceeds are intended for working capital and general corporate purposes, including R&D, manufacturing, commercialization and strategic transactions; management retains broad discretion over use.

  • Pending deployment, proceeds may be invested; the base prospectus specifies short-term, investment-grade interest-bearing obligations, CDs or U.S. government obligations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Zura Bio earnings date

Logotype for Zura Bio Limited
Q4 202619 Mar, 2027
Zura Bio
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Zura Bio earnings date

Logotype for Zura Bio Limited
Q4 202619 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. It leverages multi-asset immunology to create novel dual-pathway antibodies, including tibulizumab, ZB-168, and torudokimab, which are designed to address autoimmune diseases and other conditions with unmet medical needs. These therapies have completed early-phase studies and are advancing towards further clinical development. Zura Bio Limited is headquartered in Henderson, Nevada, and its shares are listed on NASDAQ.